Entrada Therapeutics, Inc. Common Stock
TRDAEntrada Therapeutics, Inc. is a biotechnology company focused on developing intracellular biologic therapies. Utilizing its proprietary platform, the company aims to create innovative treatments for diseases with high unmet medical needs by delivering therapeutic molecules directly into cells.
Company News
Entrada Therapeutics reported progress across its RNA-based therapeutic pipeline, with multiple clinical programs in development for Duchenne muscular dystrophy (DMD) and expansion into ocular diseases. The company expects to report data from ELEVATE-44-201 in Q2 2026 and ELEVATE-45-201 in mid-2026, initiate a Phase 1/2 study for ENTR-601-50 by e...
Questex's Fierce Biotech and Fierce Pharma announced the 2025 Life Sciences Innovation Awards, recognizing groundbreaking companies across various technological domains in healthcare and biotechnology.
5AM Venture Management sold its entire 189,593 share stake in Viking Therapeutics, representing a $5.02 million position change. The sale appears to be a portfolio rebalancing rather than a lack of confidence in the company's potential.
Entrada Therapeutics awarded $50,000 grants to Jett Foundation and Parent Project aps to support Duchenne muscular dystrophy community initiatives focused on equity, accessibility, and inclusion in the U.S. and Italy.
Entrada Therapeutics reported a significant revenue drop and wider-than-expected loss in Q2 2025, primarily due to the conclusion of its partnership with Vertex Pharmaceuticals. Despite financial challenges, the company continues advancing its clinical pipeline for neuromuscular and genetic disease therapies.
